Last month, Elodie, Magali, and I found ourselves in Lisbon—not for a spring getaway (though the weather was a delightful preview of the season) and certainly not for ultra-trail training (although the city’s hills did give our calves a solid workout!). Instead, we were there for EIP, an event that joined experts from around the world, diving deep into the latest bioanalytical challenges and innovations in immunogenicity.
The conference was packed with insightful discussions on hot topics, from Immunogenicity Risk Assessment (IRA) to the nuances of singlicate analysis in Ligand Binding Assays (LBA). We dove into debates on signal-to-noise ratio (S/N) versus titer, the implications of omitting the confirmatory tier in the gold-standard three-tiered approach, and the ever-relevant topic of pre-existing Anti-Drug Antibodies (ADAs).
One thing we missed this year was the regulatory perspective from the FDA, as their representatives couldn’t attend. Their insights would have been invaluable, but the discussions remained dynamic, with experts sharing diverse viewpoints and experiences.
Of course, EIP isn’t just about the technical deep dives—it’s also about connection. Thanks to the impeccable organization of Barbara Vercruyssen and Daniel Kramer, the event was as smooth as it was enriching. Whether over coffee breaks, lunch conversations, or the unforgettable Gala dinner (seriously, even the French gourmets among us were impressed), the networking opportunities were just as valuable as the sessions themselves.
It is also the yearly show of the EIP choir, with Barbara as the choirmaster and Daniel as the principal soloist.
Until next time, EIP—Lisbon, you’ve set the bar high!